Want to see TSE:TLT full AI Analyst Report?
Total Valuation
Theralase Technologies has a market cap or net worth of C$57.44M. The enterprise value is C$67.31.
Market CapC$57.44M
Enterprise ValueC$67.31
Share Statistics
Theralase Technologies has 310,483,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding310,483,300
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Theralase Technologies’s return on equity (ROE) is -2.32 and return on invested capital (ROIC) is -186.74%.
Return on Equity (ROE)-2.32
Return on Assets (ROA)-1.18
Return on Invested Capital (ROIC)-186.74%
Return on Capital Employed (ROCE)-2.23
Revenue Per Employee51.03K
Profits Per Employee-257.55K
Employee Count16
Asset Turnover0.23
Inventory Turnover1.14
Valuation Ratios
The current PE Ratio of Theralase Technologies is ―. Theralase Technologies’s PEG ratio is 1.28.
PE Ratio―
PS Ratio51.16
PB Ratio23.49
Price to Fair Value23.49
Price to FCF-12.52
Price to Operating Cash Flow-15.50
PEG Ratio1.28
Income Statement
In the last 12 months, Theralase Technologies had revenue of 816.47K and earned -4.12M in profits. Earnings per share was -0.02.
Revenue816.47K
Gross Profit241.51K
Operating Income-4.18M
Pretax Income-4.12M
Net Income-4.12M
EBITDA-3.91M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -3.39M and capital expenditures 21.45K, giving a free cash flow of -3.37M billion.
Operating Cash Flow-3.39M
Free Cash Flow-3.37M
Free Cash Flow per Share-0.01
Dividends & Yields
Theralase Technologies pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.19
52-Week Price Change-2.63%
50-Day Moving Average0.23
200-Day Moving Average0.24
Relative Strength Index (RSI)34.29
Average Volume (3m)356.56K
Important Dates
Theralase Technologies upcoming earnings date is Dec 2, 2026, TBA (Confirmed).
Last Earnings DateAug 28, 2026
Next Earnings DateDec 2, 2026
Ex-Dividend Date―
Financial Position
Theralase Technologies as a current ratio of 1.25, with Debt / Equity ratio of 2.17%
Current Ratio1.25
Quick Ratio0.94
Debt to Market Cap<0.01
Net Debt to EBITDA-0.07
Interest Coverage Ratio-99.25
Taxes
In the past 12 months, Theralase Technologies has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Theralase Technologies EV to EBITDA ratio is -10.75, with an EV/FCF ratio of -12.61.
EV to Sales51.49
EV to EBITDA-10.75
EV to Free Cash Flow-12.61
EV to Operating Cash Flow-12.80
Balance Sheet
Theralase Technologies has C$5.26M in cash and marketable securities with C$148.72K in debt, giving a net cash position of C$5.11M billion.
Cash & Marketable SecuritiesC$5.26M
Total DebtC$148.72K
Net CashC$5.11M
Net Cash Per ShareC$0.02
Tangible Book Value Per Share<C$0.01
Margins
Gross margin is 44.21%, with operating margin of -511.39%, and net profit margin of -504.71%.
Gross Margin44.21%
Operating Margin-511.39%
Pretax Margin-504.71%
Net Profit Margin-504.71%
EBITDA Margin-478.86%
EBIT Margin-499.56%
Analyst Forecast
The average price target for Theralase Technologies is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-24.86%
EPS Growth Forecast18.29%